Kiniksa Pharmaceuticals Ltd (KNSA)vsNovartis AG ADR (NVS)
KNSA
Kiniksa Pharmaceuticals Ltd
$52.99
-1.60%
HEALTHCARE · Cap: $4.08B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8250% more annual revenue ($56.58B vs $677.56M). NVS leads profitability with a 23.9% profit margin vs 8.7%. NVS trades at a lower P/E of 21.2x. NVS earns a higher WallStSmart Score of 51/100 (C-).
KNSA
Buy51
out of 100
Grade: C-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$202.90
Current Price
$52.99
$149.91 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Earnings expanding 550.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 58.2x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
KNSA scores higher overall (51/100 vs 51/100) and 65.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a commitment to redefining treatment paradigms, Kiniksa presents a compelling opportunity for institutional investors seeking exposure in the biopharmaceutical sector.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?